ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 1953

Somatic Mutations in a Single Residue of UBA1 Cause VEXAS, a Severe Adult-Onset Rheumatic Disease Presenting as Relapsing Polychondritis, Polyarteritis Nodosa, or Giant Cell Arteritis

David Beck1, Marcela Ferrada2, Keith Sikora3, Amanda Ombrello4, Daniela Ospina Cardona5, Nicholas Balanda6, Wuhong Pei6, Jason Collins6, Robert Colbert7, Mariana Kaplan8, Massimo Gadina9, Sinisa Savic10, Helen Lachmann11, Kyle Retterer12, Shawn Burgess13, William Gahl6, Achim Werner6, Ivona Aksentijevich14, Neal S. Young6, Katherine R. Calvo6, Peter C. Grayson15 and Daniel Kastner16, 1National Human Genome Research Institute, Bethesda, 2Systemic Autoimmunity Branch, Vasculitis Translational Research Program, National Institute of Arthritis and Musculoskeletal and Skin Diseases, National Institutes of Health, Bethesda, MD, 3National Institutes of Health Clinical Center, Bethesda, MD, 4National Human Genome Research Institute/National Institutes of Health, Bethesda, MD, 5National Institute of Health, Bethesda, 6National Institutes of Health, Bethesda, 7Pediatric Clinical Trials Unit and Office of Clinical Director, NIAMS, NIH, Bethesda, MD, 8National Institute of Arthritis and Musculoskeletal and Skin Diseases, Bethesda, MD, 9National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS), NIH, Bethesda, MD, 10University of Leeds, England, United Kingdom, 11National Amyloidosis CenterRoyal Free Campus, Rowland Hill St, London, United Kingdom, 12GeneDX, Gaithersburg, 13National Institutes of Health, Bethesda, MD, 14National Human Genome Research Institute, Bethesda, MD, 15Systemic Autoimmunity Branch, National Institutes of Health, NIAMS, Bethesda, MD, 16National Human Genome Research Institute (NHGRI), NIH, Bethesda, MD

Meeting: ACR Convergence 2020

Keywords: Autoinflammatory diseases, genetics, giant cell arteritis, innate immunity, Vasculitis

  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print
Session Information

Date: Monday, November 9, 2020

Title: Genetics, Genomics & Proteomics (1953–1957)

Session Type: Abstract Session

Session Time: 12:00PM-12:50PM

Background/Purpose: Identifying the causes of adult-onset rheumatic diseases remains a challenge, and limits diagnosis, prognosis, and targeted treatment. We hypothesized that mutations in genes regulating the post-translational modification ubiquitin, previously implicated in two autoinflammatory diseases, may define new rheumatic disorders.

Methods: We analyzed peripheral blood exome sequence data from 2,560 individuals with inflammation-related diagnoses for deleterious mutations in >800 ubiquitin-related genes. After discovering three patients with novel UBA1 mutations, we identified additional cases based on clinical similarities. Sanger sequencing, digital droplet PCR, immunoblotting, immunohistochemistry, flow cytometry, and transcriptome/cytokine profiling were performed. CRISPR/Cas9 knockout zebrafish provided an in vivo model to assess UBA1 gene function.

Results: Twenty-eight adult males were identified with somatic mutations at methionine 41 in UBA1, an X-linked gene, encoding the major E1 enzyme that initiates ubiquitylation. Methionine 41 is highly conserved in UBA1, and these somatic mutations were not observed in exome sequences from over 80,000 healthy controls. Among affected individuals, mutations were found in more than half of hematopoietic stem cells, exclusively in peripheral blood myeloid cells, and not in lymphocytes or fibroblasts. Patients developed an often-fatal, treatment-refractory inflammatory syndrome in late adulthood, with fevers, cytopenias, characteristic vacuoles in myeloid and erythroid precursors cells, dysplastic bone marrow, neutrophilic cutaneous and pulmonary inflammation, chondritis, and vasculitis. Patients fulfilled clinical criteria for inflammatory (relapsing polychondritis, Sweet syndrome, polyarteritis nodosa, giant cell arteritis) and hematologic (myelodysplastic syndrome or multiple myeloma) conditions. Mutations at p.Met41 resulted in  loss of the cytoplasmic isoform of UBA1 and decreased ubiquitylation and, unexpectedly, the expression of a novel, catalytically inactive, toxic isoform, in mutant, but not wildtype, lineages. Mutant peripheral blood cells exhibited activated innate immune pathways and evidence for unfolded protein response (UPR). Knockout of the zebrafish UBA1 cytoplasmic isoform homologue caused systemic inflammation.

Conclusion: By querying exomes for mutations in ubiquitylation genes, we have defined a novel disorder, VEXAS (vacuoles, E1 enzyme, X-linked, autoinflammatory, somatic) syndrome, which connects seemingly unrelated adult-onset inflammatory syndromes and establishes a precedent for a new molecular taxonomy of rheumatic diseases. Our work also reveals somatic mutations as an underrecognized cause of adult-onset rheumatic diseases.


Disclosure: D. Beck, None; M. Ferrada, None; K. Sikora, None; A. Ombrello, None; D. Ospina Cardona, None; N. Balanda, None; W. Pei, None; J. Collins, None; R. Colbert, Eli Lilly and Company, 2, Eli Lilly and Company, 9; M. Kaplan, None; M. Gadina, None; S. Savic, Novartis, 5, 8, SOBI, 2, 5, 8; H. Lachmann, None; K. Retterer, Opko Health Inc, 1, 3; S. Burgess, None; W. Gahl, None; A. Werner, None; I. Aksentijevich, None; N. Young, None; K. Calvo, None; P. Grayson, None; D. Kastner, None.

To cite this abstract in AMA style:

Beck D, Ferrada M, Sikora K, Ombrello A, Ospina Cardona D, Balanda N, Pei W, Collins J, Colbert R, Kaplan M, Gadina M, Savic S, Lachmann H, Retterer K, Burgess S, Gahl W, Werner A, Aksentijevich I, Young N, Calvo K, Grayson P, Kastner D. Somatic Mutations in a Single Residue of UBA1 Cause VEXAS, a Severe Adult-Onset Rheumatic Disease Presenting as Relapsing Polychondritis, Polyarteritis Nodosa, or Giant Cell Arteritis [abstract]. Arthritis Rheumatol. 2020; 72 (suppl 10). https://acrabstracts.org/abstract/somatic-mutations-in-a-single-residue-of-uba1-cause-vexas-a-severe-adult-onset-rheumatic-disease-presenting-as-relapsing-polychondritis-polyarteritis-nodosa-or-giant-cell-arteritis/. Accessed .
  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print

« Back to ACR Convergence 2020

ACR Meeting Abstracts - https://acrabstracts.org/abstract/somatic-mutations-in-a-single-residue-of-uba1-cause-vexas-a-severe-adult-onset-rheumatic-disease-presenting-as-relapsing-polychondritis-polyarteritis-nodosa-or-giant-cell-arteritis/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology